SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs gets EIR from USFDA for Unit 2 at Visakhapatnam

23 Jan 2020 Evaluate

Laurus Labs has received an Establishment Inspection Report (EIR) (for the Pre-Approval Inspection) from US Food and Drug Administration (USFDA) for its Unit-2 (FDF&API integrated facility) located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

The Pre-Approval Inspection (PAI) was carried out from November 04, 2019 to November 08, 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1450.60 -3.35 (-0.23%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: